Inventor · disambiguated record
Scott Michael Lonning
Also filed as: LONNING SCOTT · LONNING SCOTT M · LONNING SCOTT MICHAEL
20 granted patents·5 pending applications·21 citations·filing 2011–2025
92Inventor score
Top patents by PatentIndex Score
25 records- 0193US12138314B2Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 12, 2024·1 cites·8 claims
- 0293US12138313B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 12, 2024·1 cites·8 claims
- 0389US11702481B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2017·Granted Jul 18, 2023·3 cites·19 claims
- 0489US11312769B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Apr 26, 2022·4 cites·14 claims
- 0588US11981732B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted May 14, 2024·1 cites·19 claims
- 0688US11634486B2Anti-SEZ6L2 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2017·Granted Apr 25, 2023·3 cites·4 claims
- 0783US12491256B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2023·Granted Dec 9, 2025·0 cites·18 claims
- 0882US12473358B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 18, 2025·0 cites·19 claims
- 0982US11434303B2Anti-LY6H antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Sep 6, 2022·1 cites·12 claims
- 1079US2025092132A1Anti-ilt3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Application pending·0 cites
- 1178US11932694B2Anti-VTCN1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Mar 19, 2024·1 cites·14 claims
- 1277US2025368747A1Anti-il1rap antibodies and compositionsBLUEFIN BIOMEDICINE INC·Filed 2025·Application pending·0 cites
- 1376US12427163B2Anti-VTCN1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Sep 30, 2025·0 cites·14 claims
- 1476US12296006B2Anti-LY6H antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted May 13, 2025·0 cites·14 claims
- 1576US11267886B2Anti-ILT3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Mar 8, 2022·1 cites·13 claims
- 1675US8911736B2Combination therapy for treating breast cancerHARPER JAY·Filed 2011·Granted Dec 16, 2014·4 cites·28 claims
- 1775US2023331839A1Anti-sez6l2 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2023·Application pending·0 cites
- 1873US12110326B2Anti-ILT3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted Oct 8, 2024·0 cites·22 claims
- 1973US2025319180A1Anti-ly6h antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2025·Application pending·0 cites
- 2072US9539325B2Combination therapy for treating breast cancerGENZYME CORP·Filed 2014·Granted Jan 10, 2017·1 cites·16 claims
- 2169US12350347B2Nucleic acids encoding anti-IL1RAP antibodies and their usesBLUEFIN BIOMEDICINE INC·Filed 2021·Granted Jul 8, 2025·0 cites·13 claims
- 2259US11248054B2Anti-IL1RAP antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Feb 15, 2022·0 cites·8 claims
- 2357US10507242B2Combination therapy for treating breast cancerGENZYME CORP·Filed 2017·Granted Dec 17, 2019·0 cites·4 claims
- 2442US10633437B2Treatment of myocardial infarction using TGF-β antagonistsGENZYME CORP·Filed 2016·Granted Apr 28, 2020·0 cites·20 claims
- 2537US2013330352A1Treatment of myocardial infarction using tgf beta antagonistsAKITA GEOFFREY Y·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Scott Michael Lonning files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →